German health technology company Siemens Healthineers said on Monday its first-quarter free cash flow more than doubled, boosted by stronger demand for its rapid antigen tests due to the global Covid-19 pandemic.
The company, which pre-released its core earnings results last week, said free cash flow more than doubled to 668 million euros ($810.28 million) for the three months ended Dec. 31. from 244 million a year earlier.
Net profit jumped 44% to 437 million euros, compared with 304 million euros a year earlier.
Medical technology companies were hit in the early stages of the pandemic, as patients avoided check-ups for conditions not related to the virus while hospitals put off big-ticket purchases.
Both Siemens Healthineers and Dutch rival Philips have flagged a stronger first half of 2021 as hospitals place delayed orders and demand for equipment to treat Covid-19 patients continues.
Last week, Siemens Healthineers raised its outlook for 2021 sales and earnings per share last week, citing stronger demand for its antigen tests.
It now expects full-year revenue from it rapid COVID-19 antigen test to be between 300 million euros and 350 million euros, versus the previous assumption of about 100 million euros.
"flow" - Google News
February 01, 2021 at 02:17PM
https://ift.tt/2Mpjb8L
Siemens Healthineers cash flow doubles on surge in Covid-19 tests - CNBC
"flow" - Google News
https://ift.tt/2Sw6Z5O
https://ift.tt/2zNW3tO
Bagikan Berita Ini
0 Response to "Siemens Healthineers cash flow doubles on surge in Covid-19 tests - CNBC"
Post a Comment